Disclaimer

The information provided in this website should not be construed as an offer to sell to any person, or a solicitation of any offer to buy from any person, in any jurisdiction, any interests in any products or funds, nor should it be regarded as an investment product or financial advice or be relied upon for any purpose.

While CLSA Capital Partners Limited, its subsidiaries and their respective directors, officers, employees, agents, contractors and advisers (collectively, the "CLSA Capital Partners Group") use reasonable efforts to obtain information from sources believed to be reliable, the CLSA Capital Partners Group does not make any representation or warranty as to the truth, accuracy or completeness of the information (including statements of opinion or expectation) provided in this website or as to the achievement or reasonableness of any future projections, estimates, prospects or returns or any of the assumptions underlying them. The CLSA Capital Partners Group shall not have any liability (whether arising from negligence or otherwise) for any representations (expressed or implied) contained in, or for any omissions from, the information on this website. None of the information provided in this website has been approved by any governmental or other authority in any jurisdiction.

The investments described in this website were selected to illustrate types of investments that the funds sponsored by the CLSA Capital Partners Group may pursue. Therefore, these investments are not indicative of future investments or the actual or anticipated performance of the funds, sponsored by the CLSA Capital Partners Group, through which such investments were made, nor should such investments be viewed as representative of the portfolio of investments held by such funds.

The content provided in this website is, unless otherwise specified, directed at residents of the United States and not intended for distribution to, or use by, any person or entity in any jurisdiction where such distribution or use would be contrary to law or regulation or which would subject the CLSA Capital Partners Group to any registration or other requirement within such jurisdiction. Access to this website may be limited with respect to any person, geographic region or jurisdiction, and the information contained in this website is subject to change without notice

As a result of the global outbreak of COVID-19, there have been substantial disruptions in the global financial system. As a result of these disruptions, we are relying on the relief granted in the SEC Order provided in Release IA-5469 from the requirement to file our annual amendment to Form ADV on or before 30 March 2020. We will update our Form ADV before 15 May 2020.


Disclosure

In accordance with the Financial Instruments and Exchange Law of Japan, certain information is made available for Japanese investors upon request. Please email us at Capital.Partners@clsa.com.

免責事項

当サイトに掲載しているCLSA Capital Partners Limitedの運用するファンド（以下「ファンドという。」）に関する情報は、投資に対する助言または販売の勧誘を目的としたものではありません。またこれらの情報は特定の金融商品等の売買の推奨又は投資助言を意図したものではありません。

CLSAの関連会社、並びにその役員、管理者、従業員、代理人、契約者及び助言者（以下、「CLSAキャピタルパートナーズグループ」という。）は、当サイトに掲載する内容（意見や将来の見通しについての記述を含む）に関しては万全を期しておりますが、その公正性、正確性及び完全性、並びに将来の業績、予測、及びパフォーマンスの実現性や合理性に関する記述又はその表現について、表明又は保証するものではありません。またCLSAキャピタルパートナーズグループは当サイトで掲載している情報、又はその内容における完全性及び正確性を、明示的にも黙示的にも保証しておりません。当サイトの内容は関係官庁に承認されたものではありません。

当サイトに記載された投資案件は、CLSAキャピタルパートナーズグループが過去に取り組んだ投資の一例として選択されたものであり、CLSAキャピタルパートナーズグループが将来取り組む投資の内容及びそれらの業績の予測を示すものではありません。当サイトに掲載されている情報は、その情報の配布又は使用がその地域や国の法律や規制の違反となるような地域や国、又はファンド及びCLSAキャピタルパートナーズグループが登録義務を負うような地域や国の個人または組織への配布又はこれらによる使用を意図したものではありません。


About Shenke Bio

CLSA Capital Partners’ flagship China market strategy, CLSA China Growth Strategy, completed investment in the current round of equity financing for Huzhou Shenke Biotechnology Co., Ltd. (“Shenke Bio” or the “Company”) as lead investor.

  • Key highlights
    • Shenke Bio is China’s No. 1 biotech company in Host Cell DNA (“HCD”) and protein impurity detection for use in process development and quality control
    • Product distribution is set to reach approximately 500 biopharmaceutical companies throughout China
    • China Growth Strategy played the role of lead investor
    • IPO tutoring was filed with the China Securities Regulatory Commission (Zhejiang Bureau) in Jan 2023
    • Investment decision making followed responsible investing guidelines and took ESG factors into consideration
  • Shenke Bio


  • Shenke Bio


Business profile and market leadership

Shenke Bio is a leading biotechnology company which provides analytical products to the biopharmaceutical industry for use in process development and quality control in China.

Founded in 2012, Shenke Bio specializes in providing Host Cell DNA and Host Cell Protein (“HCP”) impurity detection solutions to clients including biopharmaceuticals and CRO/CDMOs (“Contract Research Organization”/“Contract Development and Manufacturing Organization”). Impurity detection is a common workflow and part of quality control for biologics drugs. HCD and HCP standardized test kits represent the newest iteration of technology in biologics detection.

Shenke Bio


Shenke Bio is the uncontested leader in China’s impurity detection solution market. Following improvements in official standards of quality control and the rapid growth of downstream demand, Shenke Bio is well-positioned to continuously benefit from the ongoing expansion of the impurity detection market in China. The Company is expected to deliver strong and sustainable growth.




ESG considerations

As a signatory to the United Nations Principles for Responsible Investment (“UNPRI”), CLSA Capital Partners follows a proprietary set of internal responsible investing guidelines, and is committed to the thorough consideration of ESG factors in portfolio investments.

The investment in Shenke Bio demonstrates CLSA Capital Partners and CLSA China Growth Strategy approach to the application of ESG factors in the investment making process, and is pursuant with China’s broader commitment to benchmarking the pharmacopeia sector with global best practice.